

Wright State University

CORE Scholar

---

Pharmacology and Toxicology Faculty  
Publications

Pharmacology and Toxicology

---

11-21-2012

## Transfusion of CXCR4-Primed Endothelial Progenitor Cells Reduces Cerebral Ischemic Damage and Promotes Repair in db/db Diabetic Mice

Ji Chen

Wright State University - Main Campus, [ji.bihl@wright.edu](mailto:ji.bihl@wright.edu)

Jiaying Chen

Shuzhen Chen

Wright State University - Main Campus, [shuzhen.chen@wright.edu](mailto:shuzhen.chen@wright.edu)

Cheng Zhang

Liangqing Zhang

*See next page for additional authors*

Follow this and additional works at: <https://corescholar.libraries.wright.edu/ptox>



Part of the [Chemicals and Drugs Commons](#), [Endocrine System Diseases Commons](#), and the [Endocrinology, Diabetes, and Metabolism Commons](#)

---

### Repository Citation

Chen, J., Chen, J., Chen, S., Zhang, C., Zhang, L., Xiao, X., Das, A., Zhao, Y., Yuan, B., Morris, M., Zhao, B., & Chen, Y. (2012). Transfusion of CXCR4-Primed Endothelial Progenitor Cells Reduces Cerebral Ischemic Damage and Promotes Repair in db/db Diabetic Mice. *PLoS One*, 7 (11), e50105.  
<https://corescholar.libraries.wright.edu/ptox/59>

This Article is brought to you for free and open access by the Pharmacology and Toxicology at CORE Scholar. It has been accepted for inclusion in Pharmacology and Toxicology Faculty Publications by an authorized administrator of CORE Scholar. For more information, please contact [library-corescholar@wright.edu](mailto:library-corescholar@wright.edu).

---

**Authors**

Ji Chen, Jianying Chen, Shuzhen Chen, Cheng Zhang, Liangqing Zhang, Xiang Xiao, Avik Das, Yuhui Zhao, Bin Yuan, Mariana Morris, Bin Zhao, and Yanfang Chen



# Transfusion of CXCR4-Primed Endothelial Progenitor Cells Reduces Ischemic Damage and Promotes Repair in db/db Diabetic Mice

Ji Chen<sup>1</sup>, Jianying Chen<sup>1</sup>, Shuzhen Chen<sup>1</sup>, Cheng Zhang<sup>1</sup>, Liangqing Zhang<sup>1</sup>, Xiang Xiao<sup>1</sup>, Avik Das<sup>2</sup>, Yuhui Zhang<sup>1</sup>, Bin Zhao<sup>1</sup>, Yanfang Chen<sup>1</sup>

Published: November 21, 2012 • DOI: 10.1371/journal.pone.0050105

## Abstract

This study investigated the role of stromal cell-derived factor-1 $\alpha$  (SDF-1 $\alpha$ )/CXC chemokine receptor 4 (CXCR4) axis in ischemic stroke and explored the efficacy of CXCR4 primed EPCs in treating ischemic stroke in diabetes. The db/db diabetic and db/+ mice were used. Plasma SDF-1 $\alpha$  and circulating CD34+CXCR4+ cells were measured. Brain SDF-1 $\alpha$  and CXCR4 expression were quantified after middle cerebral artery occlusion (MCAO). In *in vitro* study, EPCs were transfected with adenovirus carrying null (Ad-null) or CXCR4 (Ad-CXCR4) for 4 days. For pathway block experiments, cells were pre-incubated with PI3K inhibitor or nitric oxide synthase inhibitor. Cell migration, tube formation, expression, function and apoptosis of EPCs were determined. The p-Akt/Akt and p-eNOS/eNOS expression in EPCs transfected with Ad-null or Ad-CXCR4 were measured. Ad-CXCR4 transfected EPCs were infused into mice via tail vein. On day 2 and 7, the cerebral blood flow, neurological deficit, microvascular density, angiogenesis and neurogenesis were determined. We found: 1) The levels of plasma SDF-1 $\alpha$  and circulating CD34+CXCR4+ cells were decreased in db/db mice; 2) The basal level of SDF-1 $\alpha$  and MCAO-induced up-regulation of SDF-1 $\alpha$ /CXCR4 axis were attenuated in db/db mice; 3) Ad-CXCR4 transfection increased CXCR4 expression in EPCs and enhanced EPC clonogenic forming capacity; 4) Ad-CXCR4 transfected EPCs showed reduced HG-induced dysfunction (migration and tube formation) and apoptosis via activation of PI3K/Akt/eNOS signal pathway. The efficacy of EPC infusion in attenuating infarct volume and promoting angiogenesis and neurogenesis. Our data suggest that CXCR4-primed EPCs have therapeutic effects for ischemia stroke in diabetes than unmodified EPCs do.

## Figures

**Citation:** Chen J, Chen J, Chen S, Zhang C, Zhang L, et al. (2012) Transfusion of CXCR4-Primed Endothelial Progenitor Cells Reduces Ischemic Damage and Promotes Repair in db/db Diabetic Mice. PLoS ONE 7(11): e50105. doi:10.1371/journal.pone.0050105

**Editor:** Jeffrey K. Harrison, University of Florida, United States of America

**Received:** August 2, 2012; **Accepted:** October 19, 2012; **Published:** November 21, 2012

**Copyright:** © 2012 Chen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This study was supported by the American Diabetes Association (ADA) (1-10-BS-25, Y.C.), the National Natural Science Foundation of China (HL-098637, Y.C. and HL-093567, M.M.), the National Natural Science Foundation of China (NSFC 81070878, 81270878, M.M.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

¶ These authors also contributed equally to this work.

## Introduction

Diabetes is a risk factor for stroke, which are the nation's second leading cause of death and the leading cause of long-term cerebral damage is exacerbated and the outcome is poor. The responsible mechanisms might include microvascular remodeling and impaired angiogenesis. Endothelial progenitor cells (EPCs) are believed to play an important role in maintaining endothelial function and participate in angiogenesis which represents an important endogenous tissue repair mechanism [1], [2]. Accumulating evidence shows that EPCs are reduced in number and impaired in function in diabetic patients and animals [3]–[5]. Studies on ischemic brain, heart and limbs have shown that a combination of SDF-1 $\alpha$ /CXCR4 over-expression and stem cell transfusion can reduce tissue injury, promote angiogenic repair and functional recovery [3], [6], [7]. These positive results provide a potential target for promoting repair in ischemic heart and limbs.


The stromal cell-derived factor-1 $\alpha$  (SDF-1 $\alpha$ )/CXC chemokine receptor 4 (CXCR4) axis is believed to play an important role in angiogenesis [8]–[10] and triggers many intracellular proliferation and anti-apoptosis signals, such as mitogen-activated protein kinase 3-kinase (PI3K) and the serine/threonine kinase Akt [11]. Therefore, it is a potential target for promoting repair in ischemic heart and limbs. Studies have shown that a combination of SDF-1 $\alpha$ /CXCR4 over-expression and stem cell transfusion can reduce tissue injury, promote angiogenic repair and functional recovery [3], [6], [7]. These positive results provide a potential target for promoting repair in ischemic heart and limbs. SDF-1 $\alpha$  pretreatment increases the therapeutic potential of EPC transfusion in a mouse model of ischemic stroke. CXCR4 in mesenchymal stem cells enhances *in vivo* engraftment into the ischemic heart and subsequently improves functional recovery [13]. When compared to low-CXCR4-expressing EPCs, administration of high-CXCR4-expressing EPCs promotes blood flow recovery in ischemic hindlimbs [14]. However, there is little information on EPCs-based therapy for ischemic stroke in diabetes.


In this study, we investigated whether the SDF-1 $\alpha$ /CXCR4 signal pathway is dysregulated in the brain of db/db diabetic mice. We explored the role of CXCR4/PI3K/Akt/eNOS signaling pathway and high glucose (HG) in EPC function and survival. Furthermore, we investigated whether Ad-CXCR4 primed EPCs is more effective on treating ischemic stroke in db/db mice.

## Material and Methods

### Animal Experimental Design

Adult male db/db diabetic mice (C57BL6/J) and their age matched (8–10 weeks) controls (db/+) were used for the study (Charles River, France). The general characteristics of db/+ and db/db mice are summarized in Table 1. The db/db mice possess an insulin receptor mutation and subsequently develop obesity, hyperglycemia and insulin resistance resembling adult-onset diabetes mellitus. The db/db mouse is a commonly used mouse model for type 2 diabetes [15]. The level of fasting plasma glucose was measured after 16 hours fasting using a glucose monitor (Roche Diagnostic, Indianapolis, IN). All experimental protocols (Figure 1) were approved by the Laboratory Animal Care Committee at Wright State University and Guangdong Medical College in accordance to the Guide for the Care and Use of Laboratory Animals.





**Figure 1. Experimental protocols.**

The flow diagrams briefly describe the *in vitro* and *in vivo* protocols.

doi:10.1371/journal.pone.0050105.g001

Variants	db/+ (n = 34)	db/db (n = 90)
Age (W)	8.2±0.5	8.5±0.4
B.W. (g)	27.9±0.6	44.8±1.2**
Blood glucose (mg/dl)	123.6±12.5	421.5±10.4**

Data are means ± SE.  
 \*P<0.05, \*\*P<0.01, compared with db/+. B.W.: Body weight.  
 doi:10.1371/journal.pone.0050105.t001

**Table 1. General Characteristics of db/+ and db/db Mice.**

doi:10.1371/journal.pone.0050105.t001

**Protocol one.**

For exploring whether SDF-1α/CXCR4 axis is dysregulated in the brain of diabetes (at basal and after ischemic stroke randomly assigned to middle cerebral artery occlusion (MCAO) or sham surgery group. MCAO surgery was performed as we previously described [3], [16]. Mice were euthanized 48 hours after surgery, and the brain tissues were immediately harvested. Contralateral side hemispheres were dissected for analysis of SDF-1α and CXCR4 expression. For real-time RT-PCR analysis, tissues were cut into small pieces (<0.5 cm<sup>3</sup>). After overnight, tissues were subjected to western blot analysis. For analysis of plasma SDF-1α and circulating CD34+CXCR4+ cells, tissues were immediately harvested into tubes and put on dry ice before they were transferred to the laboratory for analysis.

**Protocol two.**

For determining the therapeutic efficacy of Ad-CXCR4 primed EPCs on ischemic stroke in diabetes, bone marrow (BM) derived EPCs were cultured for 7 days and then transfected with adenovirus (Ad) carrying null (Ad-null-EPCs) or CXCR4 gene (Ad-CXCR4-EPCs). EPCs were continuously cultured for another 2 days to expansion. After that, the cells were harvested, and mice were subjected to MCAO surgery (under anesthesia by inhaling 2.5% isoflurane) and randomly assigned to different treatment groups: Vehicle (PBS), Ad-null-EPCs and Ad-CXCR4-EPCs. Pain and discomfort were minimized by an initial injection of Buprenorphine (0.05 mg/kg) and another two injections every 12 hours. Mice were injected via the tail vein with EPCs (2×10<sup>5</sup> cells/100 μl in PBS) or the vehicle (PBS) [3], [17]. To label the new generated cells, mice were injected with bromodeoxyuridine (BrdU, 65 μg/g/day, i.p.) immediately after MCAO surgery. At the experimental endpoint [18], neurologic motor function was determined and cerebral blood flow (CBF) was measured. Mice (n = 12/group/time point) were euthanized on day 2 or 7. Blood samples were taken from the heart under deep anesthesia (pentobarbital, 150 mg/kg body weight) [3]. For real-time RT-PCR analysis of CXCR4 expression (n = 6/group), the ischemic hemisphere was immediately harvested as described in Protocol one. For histological analysis (n = 6/group), the brain was fixed in 4% paraformaldehyde (PFA). Then, brain tissues were fixed in 4% PFA plus 30% sucrose for 3 days. Fixed brains were sectioned (20 μm) and divided into four wells for Fluoro-Jade staining analysis of infarct volume, and immunohistological analysis of angiogenesis and neurogenesis.

## Enzyme-linked Immunosorbent Assay (ELISA) for SDF-1 $\alpha$

The plasma level of SDF-1 $\alpha$  was measured by ELISA methods [19]. Briefly, mouse plasma was collected and detected by ELISA systems (R&D Systems, MN). Absorbance was read at 450 nm.

## Real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR)

The levels of SDF-1 $\alpha$  and CXCR4 of the brain tissues were determined using real-time RT-PCR methods [20]. Brain tissue was homogenized in RNeasy lysis kit (Qiagen, CA) and reverse-transcribed with the high capacity cDNA archive kit (Qiagen). The real-time PCR was run using the following primer sequences: CXCR4 (5'-TTT CAG CCA GCA GTT TCC TT-3' and 5'-TCA GTG GCT GAC CTC CTC TT-3'); SDF-1 $\alpha$  (5'-GTC GTG-3' and 5'-AGA GCT GGG CTC CTA CTG TGC GGC CGC GGG-3').  $\beta$ -actin was chosen for housekeeping gene expression.

## Bone Marrow EPC Culture and Characterization

EPCs were generated from BM mononuclear cells (MNCs) as we previously reported [3], [21]. In brief, BM was flushed from femoral and tibial marrow of db/+ and db/db mice. MNCs were isolated by using density gradient centrifuge method. BM MNCs isolated from db/+ and db/db mice were counted and seeded into 24-well plates (BD Bioscience, San Jose, CA, USA) and then grown in endothelial cell basal medium-2 (EBM-2) supplemented with endothelial cell growth cytokine cocktail (Lonza, Walkersville, MD, USA). After 3 days in culture, non-adherent cells were removed by washing with PBS. The medium was changed every 2 days. EPCs were characterized by double staining with Di-LDL and BS-Lectin, and flow cytometry (CD34 and VEGFR2) on day 7.

## Ad-CXCR4 Preparation and Transfection

The Ad-CXCR4 was kindly provided by Dr. Yigang Wang in the Department of Pathology and Experimental Medicine at the University of Michigan. The CXCR4 cDNA (MGC-36266) was purchased from ATCC (American Type Culture Collection) and sub-cloned in the BglIII and HindIII sites of the pAdTrack-CMV shuttle vector pAdTrack-CMV which contains the enhanced green fluorescence protein (EGFP) expression cassette. The CXCR4 cDNA was inserted into the pAdTrack-CMV shuttle vector under cytomegalovirus (CMV) promoter. EPCs were transfected with Ad-null or Ad-CXCR4. Briefly, EPCs cultured in six-well plates with 75% confluence were incubated with  $1 \times 10^7$  infectious units of Ad-null or Ad-CXCR4. After 48 hours, the viruses were removed and the medium was replaced with fresh medium with FCS in the following day. Cells were harvested at 72 hours. CXCR4 expression in EPCs was confirmed by real-time RT-PCR and western blot. The percentage of CXCR4+ EPCs was determined by flow cytometry (Accuri C6 flow cytometer, Inc. Ann Arbor, MI) after staining EPCs with anti-CXCR4 (CXCR4-PE, eBioscience). The percentage of CXCR4+ EPCs = events of CXCR4+ EPCs/total events of EPCs  $\times$  100%.

## Colony Forming Unit Counts of EPCs

EPCs from db/+ and db/db mice were cultured in EBM-2 medium and seeded in six-well plates precoated with fibronectin. After 3 days in culture, non-adherent cells were removed by washing with PBS and the adherent cells were transfected with Ad-null or Ad-CXCR4 ( $1 \times 10^7$  infectious units). After 48 hours, the viruses were removed and the medium was replaced with fresh medium with FCS in the following day. Cells were harvested at 72 hours. The numbers of colony formation unit (CFU) were counted by visual inspection with an inverted microscope. A CFU was defined as a central core of round cells with elongated sprouting cells at the periphery, as previously reported [22].

## High Glucose Experiments on EPCs

The HG (25 mmol/L) medium which corresponds to 350–450 mg/dl of plasma glucose levels in diabetic patients was used for osmotic control as previous reports [24]–[25]. Ad-null-EPCs or Ad-CXCR4-EPCs were cultured in DMEM supplemented with SDF-1 $\alpha$  (100 ng/ml) for 4 days before functional assays. The medium were changed every two days. The level of the culture supernatant was daily monitored by an oxidase-based colorimetric method [27] during the HG experiment. The cells were pre-incubated with PI3K inhibitor (LY294002, 20  $\mu$ M, Cell Signaling) or NOS inhibitor (*N*<sup>G</sup>-nitro-arginine methyl ester, L-NAME) for two hours [28].

## EPC Migration and Tube Formation Assays

EPC migration and tube formation were evaluated by using Boyden chamber (Chemicon, Rosemont, IL) and tube formation assay as previously described [3]. For migration, EPCs ( $2 \times 10^4$  cells) were placed into upper compartment of the Boyden chamber. The lower compartment contained 100 ng/ml vascular endothelial growth factor (VEGF) and 100 ng/ml stromal cell-derived factor-1 (SDF-1) in the lower compartment. Cells that migrated across the membrane were counted under an inverted light microscope, quantified and averaged by examining five fields (magnification,  $\times 200$ ). For tube formation, EPCs were seeded into 96-well plates with 10 $\times$ ECMatrix' solution (Corning) at 37°C for one hour to allow the matrix solution to solidify. EPCs were re-plated ( $1 \times 10^4$  cells/well) on top of the matrix at 37°C. Tube formation was evaluated with an inverted light microscope and defined as a tube structure. The number of independent fields were assessed for each well, and the average number of tubes per field (magnification,  $\times 200$ ) was used for tube formation assays. EPCs were cultured in the basal EPC medium as previously described [30].

## EPC Apoptosis Assay

After 4 days' culture in HG medium, EPCs were harvested for apoptosis analysis by using Alexa Fluor 488 annexin V/propidium iodide (PI) (Invitrogen, Carlsbad, CA). Briefly, cells were resuspended in annexin-binding buffer, and then incubated with annexin V/PI at room temperature (RT). The apoptotic EPCs were recognized as PI<sup>-</sup>/Annexin V<sup>+</sup> cells. The percentage of apoptosis was calculated.

## Western Blot Analysis

Gene expression of SDF-1 $\alpha$ , CXCR4, eNOS, Akt, p-eNOS or p-Akt of the brain tissue or EPCs was determined [28]. The protein lysates were subjected to SDS-PAGE electrophoresis and transferred to nitrocellulose membranes. The membranes were blocked by incubating with 5% dry milk and Tris-buffered saline for one hour, and then incubated with primary antibodies (anti-SDF-1 $\alpha$ , CXCR4 (1:100, AnaSpec Inc. CA), Akt (1:1000, Cell Signaling Technology), eNOS (1:1000, Cell Signaling Technology), or p-eNOS (1:1000) at 4°C overnight.  $\beta$ -actin (1:4000, Sigma, MO) was used to normalize protein loading. The membranes were incubated with horseradish peroxidase (HRP) conjugated IgG (1:40000, Jackson Lab) for one hour at RT. Blots were developed using diaminobenzidine tetrahydrochloride (DAB) as substrate and quantified.

## Flow Cytometry Analysis of Circulating EPCs and CD34<sup>+</sup>CXCR4<sup>+</sup> Cells

The level of circulating EPCs was determined by flow cytometry as a previous study [3]. Briefly, circulating MNCs were isolated from peripheral blood mononuclear cells (PBMCs) and stained with anti-mouse CD34-PE (AbD Serotec, Raleigh, NC) and VEGFR2-PE-Cy7 (BD, Bioscience) antibodies. For CD34<sup>+</sup>CXCR4<sup>+</sup> cells, circulating MNCs were stained with CD34-FITC (AbD Serotec) and CXCR4-PE (eBioscience, San Diego, CA). The number of circulating EPCs and CD34<sup>+</sup>CXCR4<sup>+</sup> cells were expressed as cells/ml blood. Isotype (IgG) antibodies were used as calibration.

## Functional Evaluation of Neurological Deficits

The neurological deficit scores were evaluated on day 2 or 7 after EPC treatment for functional determination of the rotarod scale method was previously described [16], [32]. The five points are: 0, normal motor function; 1, flexion of contralateral limb by the tail; 2, circling to the contralateral side but normal posture at rest; 3, leaning to the contralateral side at rest. The neurologic behavior of mice was scored by an investigator who was unaware of animal grouping.

## Measurement of Cerebral Blood Flow

On day 2 or 7 following EPC transfusion, the relative CBF in the peri-infarct area was determined as described previously [16]. The mouse was anesthetized with 2.5% isoflurane and placed on a stereotaxic apparatus. An incision was made in the scalp to expose the peri-infarct site of ischemic ipsilateral area (2 mm posterior, 6 mm lateral to bregma) and contralateral site (2 mm posterior, 6 mm lateral to bregma). The CBF at each site (the contralateral site serves as basal normal level for calibration) were sequentially determined using a laser Doppler flowmeter (PF2B, Perimed, Järfälla, Sweden, diameter 0.5 mm). To minimize variability, the CBF was recorded at each site for at least 5 minutes. The averaged volume CBF for each site. The relative CBF was calculated using the formula: relative CBF = CBF of ipsilateral side/CBF of contralateral side.

performed CBF measurements was unaware of the information of animal grouping.

## Measurement of Infarct Volume and Cerebral Microvascular Density

As we previously described [3], [16], cerebral ischemic damage and the cMVD in peri-infarct area were revealed by s Fluoro-Jade (0.001%, Histo-chem, Jefferson, AR, USA) and CD31 (1:50, Invitrogen), respectively. Infarct volume and software (NIH).

## Analysis of Angiogenesis and Neurongogenesis

Angiogenesis and neurongogenesis in peri-infarct area were determined by using double immunofluorescence staining w 31 (endothelial cells, ECs), neuronal nuclei (NeuN), or glial fibrillary acidic protein (GFAP) [18]. Specifically, brain coro (1:50, Abcam, MA, USA), followed by incubation with cell-specific antibodies: CD31 (1:50, BD Biosciences), GFAP (1 overnight at 4°C. Next, brain sections were reacted with FITC (for BrdU) or Cy3 (for cell specific markers) conjugated 30 min at RT in the dark. The labeled ECs (BrdU+CD31+), neurons (BrdU+NeuN+) and glial cells (BrdU+GFAP+) in th counted under 6 random fields (200×). The average of five sections from rostral to caudal represented the data for ea counted by an investigator who was unaware of animal grouping.

## Statistical Analysis

All data, excepting neurologic deficit scores, are presented as mean  $\pm$  SE. The neurologic deficit scores were express scores among different groups were compared by the Kruskal–Wallis test. When the Kruskal–Wallis test showed a sig were applied. For the rest measurements, comparisons for two groups were performed by the student's t test. Multip two-way ANOVA. For all tests, a *P*-value <0.05 was considered significant.

## Results

### Baseline Characterization of Animals

The characterizations of blood glucose, age and body weight in db/db and db/+ mice used in this study are presented db/db mice had higher plasma glucose and body weight as compared with age-matched db/+ control mice. In protoco surgery (blood flow <75% of baseline) and randomized to vehicle, Ad-null-EPC or Ad-CXCR4-EPC infusion groups. Th blood glucose among different treatment groups (Table 2).

Groups	B.W. (g)	Blood glucose (mg/dl)
Vehicle, 2 day	48.2 $\pm$ 2.1	428.5 $\pm$ 10.4
Vehicle, 7 day	47.9 $\pm$ 2.2	425.8 $\pm$ 11.2
Ad-null-EPCs, 2 day	43.6 $\pm$ 1.5	421.6 $\pm$ 12.4
Ad-null-EPCs, 7 day	42.2 $\pm$ 1.5	418.4 $\pm$ 11.8
Ad-CXCR4-EPCs, 2 day	46.9 $\pm$ 1.6	424.8 $\pm$ 12.2
Ad-CXCR4-EPCs, 7 day	46.6 $\pm$ 1.1	421.5 $\pm$ 12.4

Data are means  $\pm$  SE. n = 6/group. B.W.: Body weight.  
doi:10.1371/journal.pone.0050105.t002

**Table 2. Baseline Characteristics of db/db Mice in Different Groups.**

doi:10.1371/journal.pone.0050105.t002




## The Levels of Plasma SDF-1 $\alpha$ and Circulating CD34+CXCR4+ Cells are Reduced in

The level of plasma SDF-1 $\alpha$  was significantly lower in db/db mice (1.3 $\pm$ 0.14 and 1.8 $\pm$ 0.15 pg/ml,  $P$ <0.05, db/db vs. dl CD34+CXCR4+ cells was reduced in db/db mice (260 $\pm$ 14 and 712 $\pm$ 42 cells/ml,  $P$ <0.01, db/db vs. db/+ mice,  $n$  = 9/g

## The Expression of SDF-1 $\alpha$ /CXCR4 Axis is Dysregulated in the Brain of db/db Mice at Stroke

At basal, the db/db diabetic mice had less expression of SDF-1 $\alpha$  in the brain tissue at both mRNA and protein levels ( difference in CXCR4 expression ( $P$ >0.05; Figure 2B and D). The levels of brain SDF-1 $\alpha$  and CXCR4 in the ischemic ip up-regulated in both db/db and db/+ mice 48 hours following MCAO ( $P$ <0.05 or 0.01). However, the up-regulations of ( $P$ <0.05; Figure 2). The levels of brain SDF-1 $\alpha$  and CXCR4 in the contralateral hemisphere was unaffected (data not




**Figure 2. SDF-1 $\alpha$ /CXCR4 expression in the brain of db/db mice at basal and in response to ischemia.**

(A) SDF-1 $\alpha$  mRNA expression. (B) CXCR4 mRNA expression. (C) SDF-1 $\alpha$  protein expression. (D) CXCR4 protein bands of SDF-1 $\alpha$  and CXCR4. \* $P$ <0.05, \*\* $P$ <0.01 vs. sham; #  $P$ <0.05 vs. db/+,  $n$  = 5/group in mRNA analysis,  $n$  = 5/group in protein analysis. doi:10.1371/journal.pone.0050105.g002

## EPC Characterization and CXCR4 Expression in EPCs

BM derived EPCs were defined as cells up-taking Di-LDL and binding with Bs-Lectin, as well as cells expressing CD34 (Figure 3A and B). At the end of EPC culture (7 days), the percentage of CD34+VEGFR2+ EPCs was 89 $\pm$ 3.5% ( $n$  = 3). CXCR4+ EPCs did not cause any change of the percentage of CXCR4+ EPCs (Day 0 vs. Day 7;  $P$ >0.05). The CXCR4+ EPCs




**Figure 3. Characterization of bone marrow derived EPCs.**

(A) Representative pictures showing cultured EPCs by double staining analysis. Red: Di-LDL up-taking; Green: Bs Yellow: Di-LDL and Bs-Lectin positive cells defined as EPCs. Scale bar: 75  $\mu$ m. (B) Representative flow plot show expression in EPCs. At the end of EPC culture, cells were stained with CD34 and VEGFR2, and analyzed by flow CD34+VEGFR+ cells. (C) Summarized data of CXCR4 expressing EPCs after day 0 and 7 days' culture. \*\* $P$ <0.01' doi:10.1371/journal.pone.0050105.g003

## Ad-CXCR4 Transfection Increases CXCR4 Expression and Colony Forming Capacity

Real-time PCR and western blot analyses showed that Ad-CXCR4 transfection up-regulated CXCR4 expression in EF protein levels ( $P$ <0.01; Figure 4A and B). Flow cytometric result showed that Ad-CXCR4 transfection significantly incr ( $P$ <0.01; Figure 4C). The number of CFUs was decreased in EPCs from db/db mice ( $P$ <0.05 or 0.01; Figure 4D). Ad- from both db/+ and db/db mice ( $P$ <0.01; Figure 4D).




**Figure 4. CXCR4 expression and colony forming capacity of EPCs.**


CXCR4 mRNA expression (A) and protein expression (B) in EPCs after Ad-CXCR4 transfection. (C) Representative showing the percentage of CXCR4+ EPCs in Ad-null-EPCs and Ad-CXCR4-EPCs. The red line is the IgG isotype forming units of EPCs. (E) Summarized data showing the expression of CXCR4 in EPCs from both db/+ and db/db treatment. \*\* $P$ <0.01 vs. Ad-null-EPCs; \* $P$ <0.05, \*\* $P$ <0.01 vs. Con; # $P$ <0.05, ## $P$ <0.01 vs. db/+, n = 6/group. Con: medium; Ad-null-EPCs: EPCs transfected with Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4. doi:10.1371/journal.pone.0050105.g004

## Ad-CXCR4 Transfection Protects EPCs from HG-induced Dysfunction and Apoptosis PI3K/Akt/eNOS Signaling Pathway

HG incubation for 4 days significantly decreased the expression of CXCR4 in EPCs from both db/+ and db/db mice ( $F$  increased the expression of CXCR4 in EPCs from both db/+ and db/db mice ( $P$ <0.01; Figure 4E). HG incubation also formation,  $P$ <0.01; Figure 5A–B) and induced EPC apoptosis ( $P$ <0.01; Figure 5C). Ad-CXCR4 transfection prevented Figure 5A–B) and apoptosis ( $P$ <0.01; Figure 5C). Meanwhile, the expression of p-Akt/p-eNOS in EPCs was measure induced down-regulation of p-Akt/p-eNOS, whereas did not affect the expression of Akt/eNOS in EPCs. Ad-CXCR4 tr down-regulation of p-Akt and p-eNOS and increased the expression of Akt and eNOS in EPCs (Figure 6). Pre-incubat the effects of Ad-CXCR4 transfection on EPC function and apoptosis ( $P$ <0.05 or 0.01), Whereas, NOS inhibitor (L-NA ( $P$ <0.01; Figure 5).




**Figure 5. Ad-CXCR4 transfection protects down-regulation of Akt/eNOS activation in EPCs induced by HG**  
 (A) Representative western blot bands showing Akt/eNOS and p-Akt/p-eNOS expression in different treatment groups. Akt and p-Akt, and 140 kDa for eNOS and p-eNOS. (B) Summarized data on Akt/eNOS and p-Akt/p-eNOS expression. \* $P < 0.05$ , \*\* $P < 0.01$  vs. Ad-null-EPCs; \*\* $P < 0.01$  vs. Con or Osm. Con: control (basal medium); Osm: osmotic control; HG: high glucose; p-Akt: phosphorylated Akt; p-eNOS: phosphorylated eNOS; PI3K: phosphatidylinositol-3-kinase; NOS: nitric oxide synthase. Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4.  
 doi:10.1371/journal.pone.0050105.g005



**Figure 6. Ad-CXCR4 transfection protects EPCs from HG-induced dysfunction and apoptosis via activating Akt/eNOS**  
 Representative tube formation pictures (A1–A8) and summarized data (A9) in different treatment groups. A1: Ad-null-EPCs+Con; A2: Ad-null-EPCs+Osm; A3: Ad-null-EPCs+HG; A4: Ad-CXCR4-EPCs+Con; A5: Ad-CXCR4-EPCs+Osm; A6: Ad-CXCR4-EPCs+HG; A7: Ad-CXCR4-EPCs+HG+LY294002; A8: Ad-CXCR4-EPCs+HG+L-NAME. Scale bar: 600  $\mu$ m. Summarized data on migration ability (B) and the percentage of tube formation (A9) in different treatment groups. \* $P < 0.05$ , \*\* $P < 0.01$  vs. Ad-null-EPCs or Ad-null-EPCs+Osm; \*\*\* $P < 0.001$  vs. HG+Ad-null-EPCs; # $P < 0.05$ , ### $P < 0.001$  vs. HG+Ad-CXCR4-EPCs+LY294002, n = 6/group. Con: control (basal medium); Osm: osmotic control; HG: high glucose; Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4.  
 doi:10.1371/journal.pone.0050105.g006

## Infusion of Ad-CXCR4 Primed EPCs Enhances the Efficacy in Increasing the Level of CXCR4 Expression in the Brain

The db/db mice were treated with EPCs two hours after MCAO surgery. Infusion of Ad-null-EPCs was able to increase the level of circulating EPCs at these time points (P<0.01; Figure 7A). Infusion of Ad-CXCR4 primed EPCs further increased the level of circulating EPCs at these time points. Infusion of Ad-null-EPCs increased CXCR4 expression in the brain of ischemic side on day 7 (P<0.05) with no significant change in the contralateral side. Infusion of Ad-CXCR4 primed EPCs was more effective to increase CXCR4 expression in the ischemic hemisphere or




**Figure 7. Effects of Ad-CXCR4-EPC infusion on cEPCs, brain CXCR4 expression and cMVD in db/db mice.** (A) The level of cEPCs in each therapeutic group. (B) The CXCR4 expression in the brain of db/db mice in each therapeutic group. (C) Pictures of cMVD (CD31 immunostaining) in the peri-infarct area. Scale bar: 50  $\mu$ m. (D) The level of cMVD in the brain of db/db mice in each therapeutic group. \* $P$ <0.05, \*\* $P$ <0.01 vs. vehicle; + $P$ <0.05, ++ $P$ <0.01 vs. Ad-null-EPCs; § $P$ <0.05 vs. day 2,  $n = 6$ /group. cEPCs: circulating endothelial progenitor cells, cMVD: cerebral microvascular density; Ad-null-EPCs: EPCs transfected with Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4. doi:10.1371/journal.pone.0050105.g007

## Infusion of Ad-CXCR4 Primed EPCs Enhances the Efficacy in Increasing cMVD in the Peri-infarct Area

Infusion of Ad-null-EPCs was able to increase the cMVD in peri-infarct area in db/db mice (Day 2,  $P$ <0.05; Day 7,  $P$ <0.01) and transfusion of Ad-CXCR4 primed EPCs could enhance the efficacy ( $P$ <0.01; Figure 7C and D).

## Infusion of Ad-CXCR4 Primed EPCs Enhances the Efficacy in Increasing Relative Cerebral Blood Flow and Reducing Neurologic Deficit Score

In agreement with the findings in cMVD, we also found that Ad-null-EPC transfusion improved the relative CBF of peri-infarct area (Figure 8A) and transfusion of Ad-CXCR4 primed EPCs was more effective (Day 2,  $P$ <0.05; Day 7,  $P$ <0.01; Figure 8A) after Ad-null-EPC infusion, and was able to be further decreased after the both day 2 and day 7 ( $P$ <0.01; Figure 8B). To evaluate the neurologic motor function, we measured neurologic deficit score after EPC infusion. We found that the neurologic deficit score was reduced in Ad-null-EPC group on day 7 ( $P$ <0.01; Figure 8C) and improved neurologic motor function as early as on day 2 and had better efficacy on day 7 ( $P$ <0.01; Figure 8C).




-EPCs      -EPCs

**Figure 8. Effects of Ad-CXCR4-EPC infusion on CBF, infarct volume and neurologic deficit score in db/db mice.** (A) The relative CBF in peri-infarct area in each therapeutic group. (B) The infarct volume in each therapeutic group. \* $P < 0.05$ , \*\* $P < 0.01$  vs. vehicle; + $P < 0.05$ , ++ $P < 0.01$  vs. Ad-null-EPCs; § $P < 0.05$  vs. day 2, n = 6/group. Ad-null-EPCs: EPCs transfected with Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4. doi:10.1371/journal.pone.0050105.g008

### Infusion of Ad-CXCR4 Primed EPCs Enhances the Efficacy in Promoting Angiogenesis

Figure 9A shows representative pictures of angiogenesis (BrdU+CD31+), glial (BrdU+GFAP+) and neuronal (BrdU+NeuN+) Data showed that Ad-null-EPC transfusion increased angiogenesis and neurogenesis on day 7 ( $P < 0.05$  or 0.01; Figure 9B–D). Moreover, transfusion of Ad-CXCR4 primed EPCs promoted angiogenesis as early as day 2 ( $P < 0.01$ ), and had better neurogenesis on day 7 ( $P < 0.01$  or 0.05; Figure 9B–D).



**Figure 9. Infusion of Ad-CXCR4-EPCs increases angiogenesis and neurogenesis in db/db mice following ischemia.** (A) Representative pictures of angiogenesis (BrdU+CD31+), neurogenesis (BrdU+NeuN+) and glia cell genesis (BrdU+GFAP+) after Ad-CXCR4-EPC treatment. Scale bar: 50  $\mu$ m. Histogram showing the number of BrdU+CD31+ (B), BrdU+NeuN+ (C) and BrdU+GFAP+ (D) cells in peri-infarct area on day 2 and 7 in different therapeutic groups. \* $P < 0.05$ , \*\* $P < 0.01$  vs. vehicle; + $P < 0.05$ , ++ $P < 0.01$  vs. Ad-null-EPCs; § $P < 0.05$  vs. day 2, n = 6/group. NeuN: neuronal nuclei; GFAP: glial fibrillary acidic protein; Ad-null-EPCs: EPCs transfected with Ad-null; Ad-CXCR4-EPCs: EPCs transfected with Ad-CXCR4. doi:10.1371/journal.pone.0050105.g009

### Discussion

There are three major findings in this present study. Firstly, we found that the expression of SDF-1 $\alpha$ /CXCR4 axis is dy

at basal and in response to ischemic stroke. Secondly, we illustrated that Ad-CXCR4 primed EPCs display resistance through activation of CXCR4 downstream PI3K/Akt/eNOS signal pathway. Thirdly, we demonstrated that infusion of A efficacy in reducing ischemic injury as well as promoting recovery.

The SDF-1 $\alpha$  regulates tissue/organ homeostasis through the CXCR4 receptor expressed in hematopoietic progenitors. SDF-1 $\alpha$  expression is reduced at basal and that ischemia-induced up-regulation of brain SDF-1 $\alpha$  and CXCR4 are less first evidence showing the dysregulation of SDF-1 $\alpha$ /CXCR4 axis in the brain of an animal model with diabetes. A previ SDF-1 $\alpha$  and CXCR4 is up-regulated in the tunica media of the thoracic aortas in streptozotocin-induced type-1 diabete diabetic models have hyperglycemia, we tentatively attribute this inconsistency to different animal models and/or tissu are supported by other previous reports showing that the SDF-1 $\alpha$ /CXCR4 axis is down-regulated in the wounds of db, model used in our study has hyperglycemia, obesity and dyslipidemia and insulin resistance [15]. Therefore, it deserve besides hyperglycemia can also lead to the impairment of SDF-1 $\alpha$ /CXCR4. Our *in vitro* data showed that HG down-re suggesting that hyperglycemia per se can impair the SDF-1 $\alpha$ /CXCR4 axis [30], [37]. Furthermore, we found that HG i function, and induced EPC apoptosis. Although diabetes is a stage of severe inflammation and oxidative stress, and th mimic the situation in *in vivo*, our results are supported by the reports from others [30], [23] showing that HG induced data are also in agreement with our previous findings showing lower level of cEPCs and less cerebral microvascular d hyperglycemia should be one of the mechanisms for EPC dysfunction in diabetes. On the other hand, evidence sugge: vascular progenitors from the bone marrow [38], [39]. The db/db mice possess an inactivating gene mutation in leptin current findings in db/db mice.

In addition, we found that the levels of plasma SDF-1 $\alpha$  and circulating CD34+CXCR4+ cells are reduced in db/db mice diabetic patients [40]. Since the SDF-1 $\alpha$ /CXCR4 interaction triggers several intracellular signals including MAPKs, PI3 modulate cell migration, proliferation and apoptosis [11], we investigated the implication of SDF-1 $\alpha$ /CXCR4 axis in EPI expected, we found that Ad-CXCR4 transfection protects EPCs from HG-induced dysfunction and apoptosis. The und CXCR4 downstream PI3K/Akt/eNOS signal pathway since PI3K or eNOS inhibitor abolishes or partially blocks these p agreement with previous observations showing that SDF-1 $\alpha$ /CXCR4 interaction mediates EPC migration via Akt and e data suggest that the SDF-1 $\alpha$ /CXCR4 axis is impaired at multiple sites (brain and EPCs) in diabetes, which might hav repair (enlarged injury and delayed repair); targeting on the dysfunction of SDF-1 $\alpha$ /CXCR4 axis could offer a new ave

EPCs have been found to differentiate into ECs and contribute to angiogenic repair [42], [43]. A recent report demons infarct volume in ischemic stroke mice [7]. Yang et al [44] also demonstrated that CD34+ cells could represent a funct beneficial therapeutic effects in myocardial infarction. In patients with diabetes and db/db diabetic mice, circulating EP dysfunctional [3]–[5]. Our previous study demonstrates that transfusion of EPCs from non-diabetic sources has benefi reports by others also suggest that EPCs be useful for therapeutic purposes in diabetes [21], [45]. Because of the me hyperlipemia, etc) changes in diabetes, the efficacy of EPC-based therapy may be limited. This evidence provides a g treating ischemic stroke in diabetes. On the other hand, this evidence suggests the control of metabolic factors in diat efficacy of EPC-based therapy. Here, we conducted *in vivo* studies to evaluate whether Ad-CXCR4 primed EPCs cou treating ischemic stroke in the db/db diabetic mice. In agreement with previous reports showing transfusion of CXCR4 cells has better efficacy than CXCR4 low-expressing cells in treating hindlimb ischemia and myocardial infarction [14], EPCs have better effects over EPCs in alleviating cerebral damage (decreasing the infarct volume, improving neurolog (increasing cMVD, angiogenesis and neurogenesis). Angiogenesis is a vital component of tissue repair processes. EP angiogenesis which represents an important endogenous tissue repair mechanism. The underlying mechanisms of EPI demonstrated. One is that EPCs physically participate in angiogenesis by incorporating and differentiating into mature angiogenic factors promoting the proliferation and survival of resident ECs [6]. In this study, we measured newly gene angiogenesis as commonly used by others [18], [47]. We found that the level of CD31+BrdU+ cells was increased in t more seen after infusion of CXCR4 primed EPCs. Our data demonstrate that CXCR4 over-expressing EPC further inc stroke.

The EPCs are thought to be a mixture of progenitor cells and mononuclear cells. At present, isolation of pure populati characterization of the different types of EPC is currently an open issue with debate [48]. However, the generally acce expression of surface markers including CD34, CD133 and KDR [49]. In this study, we cultured EPCs for 7 days and i We found the percentage of CD34+VEGFR2+ cells was about 88.5%, suggesting most of them are EPCs. Moreover, also important to obtain the high purity EPCs. We isolated BM MNCs by gradient density separation method. BM MNC 24-well plates and grown in endothelial cell basal medium-2 containing EPC growth cytokine cocktails in favor of the p

lines [21], [50]. After 3 days of culture, non-adherent cells were removed by washing with PBS to avoid contamination the observed effects are attributed to the transfused EPCs, rather than the CD45+ mononuclear cells.

Our *in vitro* EPC culture and *in vivo* animal studies are in a good agreement for supporting the beneficial effects of Ad-CXCR4 stroke. Firstly, Ad-CXCR4 transfection protects EPCs from HG induced apoptosis resulting in increased level of circuli prevents EPCs from HG-induced dysfunction (migration and tube formation) and leads to the promotion of angiogenes increases angiogenesis in peri-infarct area as early as day 2, whereas transfusion of EPCs shows this effect on day 7 cMVD and relative CBF on day 2 in EPC treatment group. Although the underline mechanism is unclear, we tentatively which secrete angiogenic factors promoting the proliferation and survival of resident ECs. Another major finding of our more effective than non primed EPCs in promoting cerebral repair processes. This is evidenced by increased angioge the Ad-CXCR4 primed EPC treatment group.

In summary, the present study demonstrates that transfusion of Ad-CXCR4 primed EPCs may be a novel approach fo stroke in diabetes. Over-expression of CXCR4 in EPCs prevents the deleterious effects of HG on EPC function and a which could be the underlying mechanism for the beneficial effects of Ad-CXCR4 primed EPC transfusion. Here, we w determine the level of EPC incorporation into endothelium, the level of local SDF-1 $\alpha$  after EPC transfusion, and the pa deserve future investigation.

## Acknowledgments

The authors thank Dr. Yigang Wang in the Department of Pathology and Experimental Medicine at University of Cincin

## Author Contributions

Conceived and designed the experiments: Ji Chen Jianying Chen BZ YC. Performed the experiments: Ji Chen Jianying data: Ji Chen Jianying Chen SC CZ XX LZ AD YZ. Contributed reagents/materials/analysis tools: MM. Wrote the papir manuscript: Ji Chen MM YC.

## References

1. Werner N, Nickenig G (2006) Influence of cardiovascular risk factors on endothelial progenitor cells: limitations 26: 257–266.  
View Article • PubMed/NCBI • Google Scholar
2. Quirici N, Soligo D, Caneva L, Servida F, Bossolasco P, et al. (2001) Differentiation and expansion of endothel cells. Br J Haematol 115: 186–194. doi: 10.1046/j.1365-2141.2001.03077.x  
View Article • PubMed/NCBI • Google Scholar
3. Chen J, Chen S, Chen Y, Zhang C, Wang J, et al. (2011) Circulating endothelial progenitor cells and cellular m mouse: possible implications in cerebral ischemic damage. Am J Physiol Endocrinol Metab 301: E62–E71. doi View Article • PubMed/NCBI • Google Scholar
4. Fadini GP, Miorin M, Facco M, Bonamico S, Baesso I, et al. (2005) Circulating endothelial progenitor cells are of type 2 diabetes mellitus. J Am Coll Cardiol 45: 1449–1457. doi: 10.1016/j.jacc.2004.11.067  
View Article • PubMed/NCBI • Google Scholar
5. Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, et al. (2002) Human endothelial progenitor cells from adhesion, and incorporation into vascular structures. Circulation 106: 2781–2786. doi: 10.1161/01.cir.0000039  
View Article • PubMed/NCBI • Google Scholar

6. Kalka C, Masuda H, Takahashi T, Kalka-Moll WM, Silver M, et al. (2000) Transplantation of ex vivo expanded neovascularization. *Proc Natl Acad Sci U S A* 97: 3422–3427. doi: 10.1073/pnas.97.7.3422  
View Article • PubMed/NCBI • Google Scholar
7. Fan Y, Shen F, Frenzel T, Zhu W, Ye J, et al. (2010) Endothelial progenitor cell transplantation improves long-t 488–497. doi: 10.1002/ana.21919  
View Article • PubMed/NCBI • Google Scholar
8. De FE, Porcelli D, Torella AR, Straino S, Iachininoto MG, et al. (2004) SDF-1 involvement in endothelial pheno marrow progenitor cells. *Blood* 104: 3472–3482. doi: 10.1182/blood-2003-12-4423  
View Article • PubMed/NCBI • Google Scholar
9. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M, et al. (2003) Stromal cell-derived factor-1 effects recruitment for ischemic neovascularization. *Circulation* 107: 1322–1328. doi: 10.1161/01.cir.0000055313.775  
View Article • PubMed/NCBI • Google Scholar
10. Tepper OM, Carr J, Allen RJ Jr, Chang CC, Lin CD, et al. (2010) Decreased circulating progenitor cell number factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair. *Diabetes* 59: 1974–1983. doi: View Article • PubMed/NCBI • Google Scholar
11. Ganju RK, Brubaker SA, Meyer J, Dutt P, Yang Y, et al. (1998) The alpha-chemokine, stromal cell-derived fac G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. *J Biol Chem* 273: 23  
View Article • PubMed/NCBI • Google Scholar
12. Zemani F, Silvestre JS, Fauvel-Lafeve F, Bruel A, Vilar J, et al. (2008) Ex vivo priming of endothelial progenitor increase their proangiogenic potential. *Arterioscler Thromb Vasc Biol* 28: 644–650. doi: 10.1161/atvbaha.107.  
View Article • PubMed/NCBI • Google Scholar
13. Zhang D, Fan GC, Zhou X, Zhao T, Pasha Z, et al. (2008) Over-expression of CXCR4 on mesenchymal stem infarcted myocardium. *J Mol Cell Cardiol* 44: 281–292. doi: 10.1016/j.yjmcc.2007.11.010  
View Article • PubMed/NCBI • Google Scholar
14. Oh BJ, Kim DK, Kim BJ, Yoon KS, Park SG, et al. (2010) Differences in donor CXCR4 expression levels are c therapeutic outcome of angiogenic treatment with endothelial colony forming cells. *Biochem Biophys Res Com* 10.1016/j.bbrc.2010.06.108  
View Article • PubMed/NCBI • Google Scholar
15. Mantzoros CS, Moschos SJ (1998) Leptin: in search of role(s) in human physiology and pathophysiology. *Clin* 10.1046/j.1365-2265.1998.00571.x  
View Article • PubMed/NCBI • Google Scholar
16. Chen S, Li G, Zhang W, Wang J, Sigmund CD, et al. (2009) Ischemia-induced brain damage is enhanced in hu transgenic mice. *Am J Physiol Regul Integr Comp Physiol* 297: R1526–R1531. doi: 10.1152/ajpregu.91040.20  
View Article • PubMed/NCBI • Google Scholar
17. Foubert P, Matrone G, Souttou B, Lere-Dean C, Barateau V, et al. (2008) Coadministration of endothelial and efficiency of proangiogenic cell-based therapy. *Circ Res* 103: 751–760. doi: 10.1161/circresaha.108.175083  
View Article • PubMed/NCBI • Google Scholar
18. Shyu WC, Lin SZ, Yang HI, Tzeng YS, Pang CY, et al. (2004) Functional recovery of stroke rats induced by gr stem cells. *Circulation* 110: 1847–1854. doi: 10.1161/01.cir.0000142616.07367.66  
View Article • PubMed/NCBI • Google Scholar
19. Yokoi H, Yamada H, Tsubakimoto Y, Takata H, Kawahito H, et al. (2010) Bone marrow AT1 augments neointin



- smooth muscle progenitors via platelet-derived SDF-1{alpha}. *Arterioscler Thromb Vasc Biol* 30: 60–67. doi: 10.1161/ATV.2005.06.1100  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
20. Cui X, Chen J, Zacharek A, Roberts C, Yang Y, et al. (2009) Nitric oxide donor up-regulation of SDF1/CXCR4 migration after stroke. *J Neurosci Res* 87: 86–95. doi: 10.1002/jnr.21836  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
21. Marrotte EJ, Chen DD, Hakim JS, Chen AF (2010) Manganese superoxide dismutase expression in endothelial diabetic mice. *J Clin Invest* 120: 4207–4219. doi: 10.1172/jci36858  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
22. Ingram DA, Lien IZ, Mead LE, Estes M, Prater DN, et al. (2008) In vitro hyperglycemia or a diabetic intrauterine colony-forming cell numbers and function. *Diabetes* 57: 724–731. doi: 10.2337/db07-1507  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
23. Chen YH, Lin SJ, Lin FY, Wu TC, Tsao CR, et al. (2007) High glucose impairs early and late endothelial progenitor cell migration: not oxidative stress-mediated mechanisms. *Diabetes* 56: 1559–1568. doi: 10.2337/db06-1103  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
24. Jie W, Wang X, Zhang Y, Guo J, Kuang D, et al. (2010) SDF-1alpha/CXCR4 axis is involved in glucose-potentiated migration of endothelial progenitor cells to vascular smooth muscle cells. *Int J Exp Pathol* 91: 436–444. doi: 10.1111/j.1365-2613.2010.00720.x  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
25. Mendoza-Naranjo A, Cormie P, Serrano AE, Wang CM, Thrasivoulou C, et al. (2012) Overexpression of the glucose transporter 1 in diabetic foot ulcers can retard fibroblast migration. *Cell Biol Int*. doi: 10.1002/cbin.12000
26. Kitahata Y, Nunomura S, Terui T, Ra C (2010) Prolonged culture of mast cells with high-glucose medium enhances chemotactic response and leukotriene C4 production. *Int Arch Allergy Immunol* 152 Suppl 122–31. doi: 10.1159/000312122  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
27. Ghorbani A, Omrani GR, Hadjzadeh MA, Varedi M (2011) Effects of rat C-peptide-II on lipolysis and glucose uptake in adipocytes. *Clin Endocrinol Diabetes* 119: 343–347. doi: 10.1055/s-0031-1275662  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
28. Zheng H, Dai T, Zhou B, Zhu J, Huang H, et al. (2008) SDF-1alpha/CXCR4 decreases endothelial progenitor cell migration via PI3K/Akt/eNOS pathway. *Atherosclerosis* 201: 36–42. doi: 10.1016/j.atherosclerosis.2008.02.011  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
29. Chen TG, Chen JZ, Wang XX (2006) Effects of rapamycin on number, activity and eNOS of endothelial progenitor cells. *Int J Exp Pathol* 97: 117–125. doi: 10.1111/j.1365-2184.2006.00375.x  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
30. Hamed S, Brenner B, Abassi Z, Aharon A, Daoud D, et al. (2010) Hyperglycemia and oxidized-LDL exert a deleterious effect on endothelial progenitor cell migration in type 2 diabetes mellitus. *Thromb Res* 126: 166–174. doi: 10.1016/j.thromres.2010.03.002  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
31. Leu S, Sun CK, Sheu JJ, Chang LT, Yuen CM, et al. (2011) Autologous bone marrow cell implantation attenuates myocardial infarction-induced heart dysfunction in porcine myocardial infarction: An echocardiographic, six-month angiographic, and molecular-cytogenetic study. *Int J Cardiol* 150: 10–17. doi: 10.1016/j.ijcard.2010.03.007  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
32. Yang G, Chan PH, Chen J, Carlson E, Chen SF, et al. (1994) Human copper-zinc superoxide dismutase transgene expression protects against neuronal injury after focal cerebral ischemia. *Stroke* 25: 165–170. doi: 10.1161/01.str.25.1.165  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

33. Girouard H, Lessard A, Capone C, Milner TA, Iadecola C (2008) The neurovascular dysfunction induced by an  
dimorphic. *Am J Physiol Heart Circ Physiol* 294: H156–H163. doi: 10.1152/ajpheart.01137.2007  
View Article • PubMed/NCBI • Google Scholar
34. Borlongan CV, Lind JG, Ilon-Carter O, Yu G, Hadman M, et al. (2004) Bone marrow grafts restore cerebral bl  
Brain Res 1010: 108–116. doi: 10.1016/j.brainres.2004.02.072  
View Article • PubMed/NCBI • Google Scholar
35. Bermudez DM, Xu J, Herdrich BJ, Radu A, Mitchell ME, et al. (2011) Inhibition of stromal cell-derived factor-1:  
Vasc Surg 53: 774–784. doi: 10.1016/j.jvs.2010.10.056  
View Article • PubMed/NCBI • Google Scholar
36. Badillo AT, Chung S, Zhang L, Zoltick P, Liechty KW (2007) Lentiviral gene transfer of SDF-1alpha to wounds i  
143: 35–42. doi: 10.1016/j.jss.2007.03.051  
View Article • PubMed/NCBI • Google Scholar
37. Ceradini DJ, Yao D, Grogan RH, Callaghan MJ, Edelstein D, et al. (2008) Decreasing intracellular superoxide  
vessel formation in diabetic mice. *J Biol Chem* 283: 10930–10938. doi: 10.1074/jbc.m707451200  
View Article • PubMed/NCBI • Google Scholar
38. Schroeter MR, Stein S, Heida NM, Leifheit-Nestler M, Cheng IF, et al. (2012) Leptin promotes the mobilization  
neovascularization by NOX2-mediated activation of MMP9. *Cardiovasc Res* 93: 170–180. doi: 10.1093/cvr/cvr  
View Article • PubMed/NCBI • Google Scholar
39. Schroeter MR, Leifheit M, Sudholt P, Heida NM, Dellas C, et al. (2008) Leptin enhances the recruitment of enc  
after vascular injury by promoting integrin-mediated adhesion. *Circ Res* 103: 536–544. doi: 10.1161/circresaha  
View Article • PubMed/NCBI • Google Scholar
40. Egan CG, Lavery R, Caporali F, Fondelli C, Laghi-Pasini F, et al. (2008) Generalised reduction of putative end  
peripheral blood cells in type 2 diabetes. *Diabetologia* 51: 1296–1305. doi: 10.1007/s00125-008-0939-6  
View Article • PubMed/NCBI • Google Scholar
41. Zheng H, Fu G, Dai T, Huang H (2007) Migration of endothelial progenitor cells mediated by stromal cell-derive  
signal transduction pathway. *J Cardiovasc Pharmacol* 50: 274–280. doi: 10.1097/fjc.0b013e318093ec8f  
View Article • PubMed/NCBI • Google Scholar
42. Asahara T, Murohara T, Sullivan A, Silver M, van der ZR, et al. (1997) Isolation of putative progenitor endothel  
964–967. doi: 10.1126/science.275.5302.964  
View Article • PubMed/NCBI • Google Scholar
43. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, et al. (1999) Bone marrow origin of endothelial proge  
vasculogenesis in physiological and pathological neovascularization. *Circ Res* 85: 221–228. doi: 10.1161/01.re  
View Article • PubMed/NCBI • Google Scholar
44. Yang J, Li M, Kamei N, Alev C, Kwon SM, et al. (2011) CD34+ cells represent highly functional endothelial pro  
6: e20219. PONE-D-10–06134 [pii]. doi:10.1371/journal.pone.0020219.
45. Cheng Y, Guo S, Liu G, Feng Y, Yan B, et al. (2012) Transplantation of bone marrow-derived endothelial prog  
fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats. *Int J Mol Med*. doi:10.3892/ijmm.2012
46. Tang YL, Zhu W, Cheng M, Chen L, Zhang J, et al. (2009) Hypoxic preconditioning enhances the benefit of car  
myocardial infarction by inducing CXCR4 expression. *Circ Res* 104: 1209–1216. doi: 10.1161/circresaha.109.  
View Article • PubMed/NCBI • Google Scholar

47. Kawada H, Takizawa S, Takanashi T, Morita Y, Fujita J, et al. (2006) Administration of hematopoietic cytokines after myocardial infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and endothelial progenitor cells. *Circulation* 113: 701–710. 113/5/701 [pii]; doi:10.1161/CIRCULATIONAHA.105.563668.
48. Prater DN, Case J, Ingram DA, Yoder MC (2007) Working hypothesis to redefine endothelial progenitor cells. *Leukemia* 21: 1038–1046. doi:10.1038/sj.leu.2404676.
49. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, et al. (2000) Expression of VEGFR-2 and AC133 by circulating endothelial progenitor cells: identification of a novel population of functional endothelial precursors. *Blood* 95: 952–958.  
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
50. Sen S, McDonald SP, Coates PT, Bonder CS (2011) Endothelial progenitor cells: novel biomarker and promising therapeutic target. *Journal of Cellular Biochemistry* 102: 263–283. doi:10.1002/jcb.22619